COR

Cencora, Inc.

Healthcare · $58.6B market cap

Verdict

Share price

$309.05

close of Oct 3, 2026

Fair value

$204.61

Sticker Price

Payback Price

$81.84

buy price

Overpriced

COR is Overpriced: at $309.05 it trades 51% above its fair value of $204.61. Its buy price (Payback Price) is $81.84, 74% below today's price. Business quality is limited: only 1 of 5 key numbers clears the 10% bar.

How we valued it

Free Cash Flow. Sales grew 10% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth8.4% a year✗
Equity per share growth-0.9% a year✗
Sales growth9.3% a year✗
Free cash flow growth8.6% a year✗
Return on invested capital14.6%✓

Follow COR

Get notified when it reaches its buy price of $81.84. Free.

Create a free account

Insider activity

Since Jun 18, 2026: 2 open-market purchases worth $1.2M, 2 sales worth $4.0M and 6 other filings (stock awards, tax withholding and similar). Why purchases matter

Purchases

Sales

Other filings

About Cencora, Inc.

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client…

Medical - Distribution

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works